Cargando…
CNX-012-570, a direct AMPK activator provides strong glycemic and lipid control along with significant reduction in body weight; studies from both diet-induced obese mice and db/db mice models
OBJECTIVES: AMP activated protein kinase (AMPK) regulates the coordination of anabolic and catabolic processes and is an attractive therapeutic target for T2DM, obesity and metabolic syndrome. We report the anti-hyperglycemic and anti-hyperlipidemic effects of CNX-012-570 is an orally bioavailable s...
Autores principales: | Anil, Tharappel M, Harish, Chandrashekaran, Lakshmi, Mudigere N, Harsha, KrishnaReddy, Onkaramurthy, Mallappa, Sathish Kumar, Venkatesh, Shree, Nitya, Geetha, Venkatachalaiah, Balamurali, Gundalmandikal V, Gopala, Aralakuppe S, Madhusudhan Reddy, Bobbili, Govind, Madabosse K, Anup, Mammen O, Moolemath, Yoganand, Venkataranganna, Marikunte V, Jagannath, Madanahalli R, Somesh, Baggavalli P |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3906767/ https://www.ncbi.nlm.nih.gov/pubmed/24460834 http://dx.doi.org/10.1186/1475-2840-13-27 |
Ejemplares similares
-
A novel 11β-hydroxysteroid dehydrogenase type1 inhibitor CNX-010-49 improves hyperglycemia, lipid profile and reduces body weight in diet induced obese C57B6/J mice with a potential to provide cardio protective benefits
por: Anil, Tharappel M, et al.
Publicado: (2014) -
CNX-013-B2, a unique pan tissue acting rexinoid, modulates several nuclear receptors and controls multiple risk factors of the metabolic syndrome without risk of hypertriglyceridemia, hepatomegaly and body weight gain in animal models
por: Sadasivuni, Manoj Kumar, et al.
Publicado: (2014) -
Treatment with CNX-011-67, a novel GPR40 agonist, delays onset and progression of diabetes and improves beta cell preservation and function in male ZDF rats
por: Gowda, Nagesh, et al.
Publicado: (2013) -
CNX-011-67, a novel GPR40 agonist, enhances glucose responsiveness, insulin secretion and islet insulin content in n-STZ rats and in islets from type 2 diabetic patients
por: Sunil, Venkategowda, et al.
Publicado: (2014) -
A novel GPR40 agonist, CNX-011-67, suppresses glucagon secretion in pancreatic islets under chronic glucolipotoxic conditions in vitro
por: Verma, Mahesh Kumar, et al.
Publicado: (2014)